Avantax Advisory Services Inc. Makes New $483,000 Investment in Moderna, Inc. (NASDAQ:MRNA)

Avantax Advisory Services Inc. bought a new stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 11,622 shares of the company's stock, valued at approximately $483,000.

Other hedge funds have also made changes to their positions in the company. State Street Corp raised its position in shares of Moderna by 12.1% in the 3rd quarter. State Street Corp now owns 16,847,212 shares of the company's stock worth $1,125,899,000 after buying an additional 1,823,276 shares during the period. Wellington Management Group LLP raised its stake in shares of Moderna by 21.0% in the 3rd quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company's stock valued at $349,166,000 after acquiring an additional 906,114 shares during the period. Amundi increased its holdings in Moderna by 79.8% in the 4th quarter. Amundi now owns 1,206,273 shares of the company's stock valued at $52,075,000 after purchasing an additional 535,273 shares in the last quarter. Two Sigma Advisers LP purchased a new position in Moderna in the third quarter valued at about $23,825,000. Finally, Douglas Lane & Associates LLC boosted its position in shares of Moderna by 62.9% in the fourth quarter. Douglas Lane & Associates LLC now owns 773,804 shares of the company's stock worth $32,175,000 after buying an additional 298,715 shares during the period. Institutional investors and hedge funds own 75.33% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on MRNA. The Goldman Sachs Group lowered Moderna from a "buy" rating to a "neutral" rating and cut their target price for the company from $99.00 to $51.00 in a research report on Wednesday, January 29th. Bank of America reduced their price objective on shares of Moderna from $41.00 to $34.00 and set an "underperform" rating on the stock in a research note on Tuesday, February 11th. Citigroup started coverage on Moderna in a report on Thursday, March 13th. They set a "neutral" rating and a $40.00 target price on the stock. Evercore ISI set a $50.00 price target on Moderna in a report on Friday, February 14th. Finally, Royal Bank of Canada restated a "sector perform" rating and set a $40.00 price objective on shares of Moderna in a research note on Tuesday, February 18th. Four research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $59.00.

Remove Ads

Moderna Price Performance

Shares of MRNA stock traded down $0.24 on Tuesday, hitting $33.94. The company's stock had a trading volume of 3,047,580 shares, compared to its average volume of 6,643,128. The stock has a market capitalization of $13.12 billion, a price-to-earnings ratio of -3.65 and a beta of 1.86. Moderna, Inc. has a fifty-two week low of $29.25 and a fifty-two week high of $170.47. The firm's fifty day moving average price is $34.89 and its 200-day moving average price is $45.39.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.